Durvalumab
- PDF / 169,104 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 6 Downloads / 131 Views
1 S
Durvalumab Capillary leak syndrome, cardiovascular disorder and sepsis following an off-label use: 3 case reports
In a study of real-world data on survival and safety from the German expanded access program (EAP) of 126 patients, treated from 22 November 2017 to 15 October 2018, 3 patients [ages and sexes not stated] were described, who developed fatal capillary leak syndrome (1 patient), fatal sepsis (1 patient) or fatal cardiovascular disorder (1 patient) during off-label treatment with durvalumab for locally advanced unresectable non-small-cell lung carcinoma (NSCLC) [dosages, routes and durations of treatments to reactions onsets not stated]. Faehling M, et al. Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Annals of Oncology 31 (Suppl. 4): S806-S807 abstr. 1244P, Sep 2020. Available from: URL: http://doi.org/10.1016/j.annonc.2020.08.117 803506071 [abstract]
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
